Mark Litton;Randall Schatzman;Jeffrey T.L. Smith;John A. Latham
发明人:
Jeffrey T.L. Smith,John A. Latham,Mark Litton,Randall Schatzman
申请号：
US13681501
公开号：
US20130183293A1
申请日:
2012.11.20
申请国别(地区):
US
年份:
2013
代理人:
摘要：
The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
